Campbell & CO Investment Adviser LLC Invests $1.57 Million in Bio-Rad Laboratories, Inc. $BIO

Key Points

• Campbell & CO Investment Adviser LLC acquired a stake in Bio-Rad Laboratories, purchasing 6,443 shares valued at approximately $1.57 million in Q1, as per their latest SEC filing.
• Several hedge funds have increased their holdings in Bio-Rad, with Dimensional Fund Advisors LP raising their stake by 17.5% and Bank of America growing theirs by a substantial 705.9%.
• Bio-Rad Laboratories recently reported earnings, with an EPS of $2.61, surpassing analyst expectations, and a year-over-year revenue increase of 2.1%.

Campbell & CO Investment Adviser LLC bought a new position in Bio-Rad Laboratories, Inc. (NYSE:BIO - Free Report) in the 1st quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The firm bought 6,443 shares of the medical research company's stock, valued at approximately $1,569,000.

Other institutional investors have also made changes to their positions in the company. Curat Global LLC acquired a new stake in shares of Bio-Rad Laboratories during the first quarter worth approximately $34,000. Allworth Financial LP lifted its stake in shares of Bio-Rad Laboratories by 260.0% in the first quarter. Allworth Financial LP now owns 144 shares of the medical research company's stock worth $36,000 after buying an additional 104 shares during the last quarter. Headlands Technologies LLC lifted its stake in shares of Bio-Rad Laboratories by 64.1% in the first quarter. Headlands Technologies LLC now owns 356 shares of the medical research company's stock worth $87,000 after buying an additional 139 shares during the last quarter. Skylands Capital LLC acquired a new stake in shares of Bio-Rad Laboratories in the first quarter worth $122,000. Finally, Mackenzie Financial Corp acquired a new stake in shares of Bio-Rad Laboratories in the fourth quarter worth $207,000. 65.24% of the stock is currently owned by institutional investors and hedge funds.

Bio-Rad Laboratories Price Performance

Shares of BIO traded up $0.98 during trading hours on Thursday, hitting $293.82. The stock had a trading volume of 189,617 shares, compared to its average volume of 306,717. The company's fifty day moving average is $262.35 and its two-hundred day moving average is $252.04. The company has a debt-to-equity ratio of 0.17, a current ratio of 5.12 and a quick ratio of 3.67. Bio-Rad Laboratories, Inc. has a 52 week low of $211.43 and a 52 week high of $387.99. The stock has a market capitalization of $7.95 billion, a price-to-earnings ratio of 25.05 and a beta of 0.90.

Bio-Rad Laboratories (NYSE:BIO - Get Free Report) last posted its earnings results on Thursday, July 31st. The medical research company reported $2.61 earnings per share for the quarter, topping the consensus estimate of $1.93 by $0.68. Bio-Rad Laboratories had a net margin of 12.50% and a return on equity of 4.01%. The business had revenue of $651.60 million for the quarter, compared to analyst estimates of $614.82 million. During the same quarter in the prior year, the firm earned $3.11 EPS. The firm's quarterly revenue was up 2.1% compared to the same quarter last year. Bio-Rad Laboratories has set its FY 2025 guidance at EPS. On average, analysts anticipate that Bio-Rad Laboratories, Inc. will post 10.81 EPS for the current year.

Analyst Ratings Changes

A number of analysts have recently weighed in on the stock. UBS Group reduced their price objective on shares of Bio-Rad Laboratories from $355.00 to $310.00 and set a "buy" rating for the company in a research note on Friday, May 2nd. Zacks Research raised shares of Bio-Rad Laboratories from a "strong sell" rating to a "hold" rating in a research report on Tuesday. Wall Street Zen lowered shares of Bio-Rad Laboratories from a "buy" rating to a "hold" rating in a research report on Friday, August 22nd. Wells Fargo & Company boosted their target price on shares of Bio-Rad Laboratories from $245.00 to $265.00 and gave the stock an "equal weight" rating in a research report on Friday, August 1st. Finally, Royal Bank Of Canada boosted their target price on shares of Bio-Rad Laboratories from $387.00 to $409.00 and gave the stock an "outperform" rating in a research report on Friday, August 1st. Three investment analysts have rated the stock with a Buy rating and two have issued a Hold rating to the company's stock. Based on data from MarketBeat, the company presently has a consensus rating of "Moderate Buy" and a consensus price target of $333.50.

Bio-Rad Laboratories Profile

Bio-Rad Laboratories, Inc manufactures and distributes life science research and clinical diagnostic products in the United States, Europe, Asia, Canada, and Latin America. It operates through two segments, Life Science and Clinical Diagnostics. The company develops, manufactures, and markets instruments, systems, reagents, and consumables to separate, purify, characterize, and quantitate biological materials such as cells, proteins, and nucleic acids for proteomics, genomics, biopharmaceutical production, cellular biology, and food safety markets.